Literature DB >> 17531847

Multiple sclerosis as a painful disease.

Meghan Kenner1, Uma Menon, Debra G Elliott.   

Abstract

Pain is a common problem of patients with multiple sclerosis (MS) and may be due to central/neuropathic or peripheral/somatic pathology. Rarely MS may present with pain, or pain may herald an MS exacerbation, such as in painful tonic spasms or Lhermitte's sign. In other patients, pain may become chronic as a long-term sequela of damage to nerve root entry zones (trigeminal neuralgia) or structures in central sensory pathways. Migraine headache may develop as a consequence of MS, and headache can also be a side effect of interferon treatment. The pathophysiology of pain in MS may be linked to certain plaque locations which disrupt the spinothalamic and quintothalamic pathways, abnormal impulses through motor axons, development of an acquired channelopathy in affected nerves, or involve glial cell inflammatory immune mechanisms. At this time, the treatment of pain in MS employs the use of antiepileptic drugs, muscle relaxers/antispasmodic agents, anti-inflammatory drugs, and nonpharmacological measures. Research concerning cannabis-based treatments shows promising results, and substances which block microglial or astrocytic involvement in pain processing are also under investigation.

Entities:  

Mesh:

Year:  2007        PMID: 17531847     DOI: 10.1016/S0074-7742(07)79013-X

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  13 in total

Review 1.  Neurological diseases and pain.

Authors:  David Borsook
Journal:  Brain       Date:  2011-11-08       Impact factor: 13.501

Review 2.  Long-term control of neuropathic pain in a non-viral gene therapy paradigm.

Authors:  E M Sloane; R G Soderquist; S F Maier; M J Mahoney; L R Watkins; E D Milligan
Journal:  Gene Ther       Date:  2009-03-05       Impact factor: 5.250

Review 3.  Painful and involuntary multiple sclerosis.

Authors:  Francesca Bagnato; Diego Centonze; Simonetta Galgani; Maria Grazia Grasso; Shalom Haggiag; Stefano Strano
Journal:  Expert Opin Pharmacother       Date:  2011-02-17       Impact factor: 3.889

4.  Neuronal Fc-gamma receptor I mediated excitatory effects of IgG immune complex on rat dorsal root ganglion neurons.

Authors:  Lintao Qu; Pu Zhang; Robert H LaMotte; Chao Ma
Journal:  Brain Behav Immun       Date:  2011-04-18       Impact factor: 7.217

5.  Pain, cognition and quality of life associate with structural measures of brain volume loss in multiple sclerosis.

Authors:  Nora E Fritz; Snehashis Roy; Jennifer Keller; Jerry Prince; Peter A Calabresi; Kathleen M Zackowski
Journal:  NeuroRehabilitation       Date:  2016-10-14       Impact factor: 2.138

6.  Anti-inflammatory cytokine gene therapy decreases sensory and motor dysfunction in experimental Multiple Sclerosis: MOG-EAE behavioral and anatomical symptom treatment with cytokine gene therapy.

Authors:  Evan Sloane; A Ledeboer; W Seibert; B Coats; M van Strien; S F Maier; K W Johnson; R Chavez; L R Watkins; L Leinwand; E D Milligan; A M Van Dam
Journal:  Brain Behav Immun       Date:  2008-09-20       Impact factor: 7.217

7.  Fetal cell microchimerism in the maternal mouse spinal cord.

Authors:  Guohui Zhang; Yunan Zhao; Xin-Min Li; Jiming Kong
Journal:  Neurosci Bull       Date:  2013-12-17       Impact factor: 5.203

8.  A Survey of Severity and Distribution of Musculoskeletal Pain in Multiple Sclerosis Patients; a Cross-Sectional Study.

Authors:  Masoud ShayestehAzar; Mohammad H Kariminasab; Majid Sajjadi Saravi; Mahmoud Abedini; Mehran Fazli; Seyyed Abbas Hashemi; Pedram Abdizadeh
Journal:  Arch Bone Jt Surg       Date:  2015-04

9.  A study of psychological well-being in people with multiple sclerosis and their primary caregivers.

Authors:  Mojgan Ghasemi; Yoosef Gorji; Freshteh Ashtar; Mojdeh Ghasemi
Journal:  Adv Biomed Res       Date:  2015-02-17

10.  Pain in experimental autoimmune encephalitis: a comparative study between different mouse models.

Authors:  Jianning Lu; Martina Kurejova; Laura N Wirotanseng; Ralf A Linker; Rohini Kuner; Anke Tappe-Theodor
Journal:  J Neuroinflammation       Date:  2012-10-06       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.